Literature DB >> 8595724

Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry.

P J Taylor1, A Jones, G A Balderson, S V Lynch, R L Norris, S M Pond.   

Abstract

The capacity of liquid chromatography-tandem mass spectrometry (LC-MS2) to detect and define individual components in a complex mixture has been utilized to develop a quantitative assay of the potent immunosuppressant drug, tacrolimus. Trough blood concentrations were measured in 175 samples obtained over several weeks after liver transplantation from seven patients. The assay was linear over the range of 0.2 to 100 micrograms/L. Imprecision was <8%, and accuracy was 99-101%. The turnaround time for a batch of 20 samples was 2.5 h. No interference from any of the other drugs being administered to the patients was evident. An ELISA also performed on the same samples overestimated the concentrations substantially, as indicated by a plot of the difference between the results for the two methods vs their mean. The favorable characteristics of the LC-MS2 assay, especially its sensitivity and specificity, will facilitate detailed pharmacokinetic studies of tacrolimus, particularly under circumstances in which metabolism is perturbed by either hepatic dysfunction or drug interactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8595724

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD.

Authors:  C Vidal; G I Kirchner; K F Sewing
Journal:  J Am Soc Mass Spectrom       Date:  1998-12       Impact factor: 3.109

2.  Tacrolimus trough monitoring guided by mass spectrometry without accounting for assay differences is associated with acute kidney injury in lung transplant recipients.

Authors:  Nicholas A Kolaitis; Daniel R Calabrese; Patrick Ahearn; Aida Venado; Rebecca Florez; Huey-Ling Lei; Karolina Isaak; Erik Henricksen; Emily Martinez; Tiffany Chong; Rupal J Shah; Lorriana E Leard; Mary Ellen Kleinhenz; Jeffrey Golden; Teresa De Marco; John R Greenland; Jasleen Kukreja; Steven R Hays; Paul D Blanc; Jonathan P Singer
Journal:  Am J Health Syst Pharm       Date:  2019-12-02       Impact factor: 2.637

Review 3.  Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Authors:  P E Wallemacq; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

5.  Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.

Authors:  Lutz Renders; Christian S Haas; Jan Liebelt; Martin Oberbarnscheidt; Harald O Schöcklmann; Ulrich Kunzendorf
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.